finden... was irgendwie ja seltsam ist, wenn es für caly eine Bedeutung hat...

hier die Meldungen, die ich sonst gefunden habe:

ALAMEDA, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today that it has received a letter from World Vision Africa, one of the largest NGOs (non-government organization) in Africa, outlining an intent to purchase $4 million of Calypte''s urine based HIV/AIDS tests.

In a letter dated September 16, 2003, Mr. Dida Guyo, Procurement Officer for World Vision''s Africa Regional Office in Nairobi, Kenya, stated that World Vision Africa spends over $1 million quarterly on HIV tests and that World Vision Africa commits to change this quarterly purchase of HIV tests from the standard blood tests to Calypte Biomedical''s urine based HIV/AIDS test.

The purchase is contingent upon the imminent approval of Calypte''s urine based tests by the Kenyan National Laboratory. Mr. Guyo stated that since the urine tests have been approved by the FDA, WHO and in neighboring Uganda, then he sees the Kenyan approval process a formality. Mr. Guyo also stated that there is strong support in Africa for non-invasive HIV/AIDS tests.

Jay Oyakawa, President of Calypte stated, "We are aggressively coordinating our efforts to receive final approval from the Republic of Kenya and believe that approval is imminent."

**********

Erst gestern erhielt Calypte eine Absichtserklärung von World Vision Africa, einer der größten NGOs (non-government organization) in Afrika, HIV-Urintests im Wert von $4 Millionen zu kaufen. Damit wurde nach Uganda nun auch Kenia auf das Testverfahren von Calypte aufmerksam.


World Vision Africa gibt pro Quartal $1 Million für HIV Tests aus, diese Tests nutzen als Untersuchungsmaterial allerdings Blut, womit eine nicht unerhebliche Gefahr der Ansteckung verbunden ist. Dida Guyo, der bei World Vision Africa für den Einkauf von HIV Tests verantwortlich ist, gab an, man werde sobald das Kenianische National Laboratory dem Wechsel zugestimmt hat, von den Bluttests zu Calyptes Urintest wechseln. Die Entscheidung des National Laboratories steht demnächst an und sollte auf jeden Fall positiv für Calypte ausfallen.


Guyo geht ebenfalls davon aus, dass die Zustimmung nur noch eine reine Formsache sein dürfte. Die Zulassung durch die FDA und die demnächst anstehende Empfehlung der WHO, sowie die Akzeptanz des Tests im benachbarten Uganda lassen keinen Zweifel aufkommen, dass das Verfahren herkömmlichen Tests zum HIV-Nachweis überlegen ist. Darüber hinaus geht der AIDS Experte Guyo davon aus, dass Kenia nicht das letzte Land sein wird, dass Calyptes HIV-Urintest den Vorzug geben wird.


In Afrika, so Guyo, ist die Unterstützung für nicht-invasive HIV/AIDS Tests, von denen Calpyte den ersten und bisher einzigen besitzt, sehr groß. Die Urintests von Calypte sind sogenannte EIAs (Enzyme Immuno Assays), diese Tests detektieren das HI-Virus also durch eine Antigen/Antikörper Reaktion. Befindet sich das Virus im Urin des Patienten, dann bindet der in der Testflüssigkeit enthaltene Antikörper an das Virus, im Anschluss daran kommt es zu einer durch ein Enzym ausgelösten Farbreaktion, welche das Vorhandensein des Virus anzeigt.

***********

MONROVIA, Calif., Oct 16, 2003 /PRNewswire via COMTEX/ -- A September 16 announcement from Calypte Biomedical Corporation reporting that World Vision intends to purchase $4 million worth of its urine-based HIV/AIDS test kits is incorrect. World Vision has no agreement and does not anticipate any agreement with Calypte for purchasing such kits in the future.

World Vision has extensive programming to prevent HIV infection as well as care for those affected by AIDS in Africa, Asia and elsewhere. However, it generally relies upon government health agencies to perform HIV tests and does not purchase testing kits independently.

SOURCE World Vision International


CONTACT: John A. McCoy, Media Relations Manager of World Vision
International, +1-626-301-7781, or john_mccoy@wvi.org

URL: www.worldvision.org
www.prnewswire.com

**************

das zweite ist von Fr.Hörrlein's Analyse...
"Dida Guyo, der bei World Vision Africa für den Einkauf von HIV Tests verantwortlich ist" ...
"Darüber hinaus geht der AIDS Experte Guyo davon aus, dass Kenia nicht das letzte Land sein wird, dass Calyptes HIV-Urintest den Vorzug geben wird."
... demnach scheint sich Fr.Hörrlein informiert zu haben, oder wo hat sie die Infos zu und von Guyo her? ... traue ich jedenfalls mehr als calypte
... wenn aber Guya der Mann für die HIV-Tests in Afrika ist, warum erwähnt dann das WVI ihn nicht? Ist das wirklich ein Missverständniss? Oder eine reine Formalie, dass es zwar keine direkte Absichtserklärung gibt, aber die Möglichkeit trotzdem besteht? Warum finde sich zum WV nichts auf calyptes HP? Wie gesagt fand ich die gestrige Meldung zu labone schon ein wenig seltsam...

... ich warte mal ab, wie es weiter geht

mfg ipollit  

Das es sich bei dem 4Moi Deal um einen sogenannten LOI handelte! FAKT ist, dass ein LOI ein "Vorvertrag" ist und das bei NICHzustandekommen des Vertrages Strafen fällig werden! Also erstmal herausbekommen WARUM es dementiert wurde! Wer hat den LOI nicht eingehalten und warum!

 

 

http://www.otcbb.com/asp/mp_quotes.asp?Quotes=CYPT
scheint die nicht sonderlich zu berühren:)
gibt auch noch ne unspektakuläre news(zahlen stehen an)
gucken,was noch kommt;)
mfg kram  

Grüße, ZN  

 

7.30 Uhr Ortszeit.....oder hat jemand andere Infos ?? Falls das wirklich ein Fake ist oder die Amis diese Meldung als nicht bzw. kaum relevant empfinden: Herzlichen Glückwunsch an die, die um die 1,10 Euro rein sind, denn der MACD liefert heute obendrein eigentlich ein wunderschönes: BUY (Charttechnik funktioniert aber natürlich nur, falls es keine üblen News gibt. Soweit ich das AUS DER FERNE beurteilen kann wären diese News auch nicht so übel wie es der Kurs in D eigentlich andeutet................)

also: hang lose  X 99  

Der Kurs wird da weitergehen wo er gesten stehengeblieben ist. Hysterie um vermeintliche Information bei denen es nicht einmal ne Quellenangabe gibt.
Den Kurs mit Falschmeldungen zu drücken hat noch immer funktioniert!
Ein gutes hat der ganze Cirkus, die nervösen Anleger und Tagesspieler verkaufen ihrer Papier, was die mit der "überlegten Spekulation" nur freuen kann! Fehlt blos noch das jemand was von KGVs oder derartigen Schwachsinn erzählt und damit die fallenden Kurse erklärt!  

jetzt steht da wieder die news wäre von 3:46 PM..... das sah ich schon heute morgen, doch dann waren es wieder 6:00 PM oder so

hier der link...

http://search.news.yahoo.com/search/news/?n=10&p=calypte

hat da jemand ne erklärung für mich, oder spinne total?????

 

wie gut, dass ich meine Position noch aufgestockt habe am heutigen Tag! Viel Lärm um nichts sag ich da nur!!  

Calypte's Urine Based HIV Test Receives Approval in the Republic of Kenya

ALAMEDA, Calif., Oct 17, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that the Government of Kenya has stated that Calypte's urine testing is approved for importation, allowing Calypte the rights to distribute their urine based HIV-1 antibody tests and Western blot supplemental test into that Republic. The approval letter received by Calypte Biomedical was signed by Dr. Jack Nyamongo, Director of the Kenyan National Laboratory.

The National Aids Control Programme (NASCOP) of the Kenyan Ministry of Health formally met yesterday and announced that urine based HIV/AIDS testing, developed by Calypte Biomedical, is approved for distribution in Kenya. After extensive testing, NASCOP concluded that urine testing is a viable and safe method of testing for HIV. Dr. Achala Ndinya, Senior HIV Co-Investigator in Kenya stated that "Calypte's urine test's sensitivity and specificity was very impressive in all 4 testing centers around the country, equaling the results of their preferred blood test." Dr. Ndinya also stated that he was "extremely pleased with the results and is looking forward to working with Calypte in the fight against HIV infection."

Calypte previously announced that they received a Letter of Intent from World Vision outlining a purchase of urine HIV tests. Subsequent to that announcement Calypte has learned that the procurement for AIDS related testing and treatment are required to be routed through government agencies not through humanitarian organizations. As a result the Letter of Intent announced on September 16th has been cancelled. The success of the October 15th meeting with Kenyan's Ministry of Health now allows Calypte to transact the sale of its HIV/AIDS tests directly with the appropriate government agencies of the African Republics.

Jay Oyakawa, President of Calypte Biomedical stated, "After a rigorous and thorough testing process in Kenya, we are very pleased by the results and the official approval. This builds upon recent successes in Uganda and China where Calypte's urine testing maintains its high efficacy. A recent article in the East African pointed out that possibly 30% of HIV infected Africans received the virus through needles (International Association of Safe Needle Technology in Geneva, Switzerland). These results prove that urine testing is the viable alternative to needles."

Tony Cataldo, Chairman of the Board of Calypte Biomedical, said, "With this announcement Calypte shows yet again that urine testing demonstrates the high efficacy which validates testing worldwide. Urine testing is a cost effective and scientifically proven product which is a safe alternative to blood and needles."

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.

 

Press Release Source: Calypte Biomedical Corporation


Calypte's Urine Based HIV Test Receives Approval in the Republic of Kenya
Friday October 17, 8:31 am ET


ALAMEDA, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT - News), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that the Government of Kenya has stated that Calypte's urine testing is approved for importation, allowing Calypte the rights to distribute their urine based HIV-1 antibody tests and Western blot supplemental test into that Republic. The approval letter received by Calypte Biomedical was signed by Dr. Jack Nyamongo, Director of the Kenyan National Laboratory.
ADVERTISEMENT


The National Aids Control Programme (NASCOP) of the Kenyan Ministry of Health formally met yesterday and announced that urine based HIV/AIDS testing, developed by Calypte Biomedical, is approved for distribution in Kenya. After extensive testing, NASCOP concluded that urine testing is a viable and safe method of testing for HIV. Dr. Achala Ndinya, Senior HIV Co-Investigator in Kenya stated that "Calypte's urine test's sensitivity and specificity was very impressive in all 4 testing centers around the country, equaling the results of their preferred blood test." Dr. Ndinya also stated that he was "extremely pleased with the results and is looking forward to working with Calypte in the fight against HIV infection."

Calypte previously announced that they received a Letter of Intent from World Vision outlining a purchase of urine HIV tests. Subsequent to that announcement Calypte has learned that the procurement for AIDS related testing and treatment are required to be routed through government agencies not through humanitarian organizations. As a result the Letter of Intent announced on September 16th has been cancelled. The success of the October 15th meeting with Kenyan's Ministry of Health now allows Calypte to transact the sale of its HIV/AIDS tests directly with the appropriate government agencies of the African Republics.

Jay Oyakawa, President of Calypte Biomedical stated, "After a rigorous and thorough testing process in Kenya, we are very pleased by the results and the official approval. This builds upon recent successes in Uganda and China where Calypte's urine testing maintains its high efficacy. A recent article in the East African pointed out that possibly 30% of HIV infected Africans received the virus through needles (International Association of Safe Needle Technology in Geneva, Switzerland). These results prove that urine testing is the viable alternative to needles."

Tony Cataldo, Chairman of the Board of Calypte Biomedical, said, "With this announcement Calypte shows yet again that urine testing demonstrates the high efficacy which validates testing worldwide. Urine testing is a cost effective and scientifically proven product which is a safe alternative to blood and needles."

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.

    Investor Relations Contact:
    Tim Clemensen
    212-843-9337
    email: tclemensen@rubensteinir.com




--------------------------------------------------
Source: Calypte Biomedical Corporation

Email this story - Set a News Alert
 

 

bin ich froh dass ich sämtliche aktie in USA gekauft hätte sonst wäre ich meine Position mittlerweile villeicht auch schon los.

Hut ab vor allen die heute in Germany günstig rein konnten :o))

prost

cash-money

ps. kursziel 2$ für heute steht wieder  LOL  

Panikverkauf!  

 

MACD-Kaufsignal ! (Siehe mein Posting 982)! Ärgerlich nur, dass ich heute morgen kei Geld zum Nachkaufen hatte..... dafür einigermaßen starke Nerven ! Deshalb Respekt vor allen die drin geblieben sind ! hang lose X 99

Ps: RT FRA: 1,27 €  

da kann ich ja von glück sagen,das mein erstes limit zu hoch angesetzt war(1.40/1.45€)und ich das zweite(1.25/1.30)um 14uhr,als die taxe kam,storniert hab:)
viel glück denen,die nun ne neuposition aufbauen müssen
gz an alle,die noch drin sind bzw nachgekauft haben
mfg kram  

wenn ihr es auch seid.
Immanuel  

ich hatte auch Glück - hab nen SL bei 1,08 gesetzt - wurde zum Glück nicht ausgeführt ;-))

B.  

kram  

ist die Geschichte mit Worldvision und der getilgten Nachricht vergessen. Da hat Calypte aber Glück, daß jetzt die Meldung mit Kenia kam.Nehmt mirs nicht übel, aber irgendwie hat die Sache noch n bitteren Geschmack. Natürlich kann Calypte auch noch bis 5 laufen, allerdings nur auf Kosten derer, die wirklich dort auch noch bereit sind zu kaufen. Jede Woche ne neue Meldung, einige positive Analystenstimmen und die Herde rennt dorthin, wo sie hinrennen soll. Meiner Ansicht nach hockt doch hier schon jeder drin, der drinnehocken kann. Macht,was ihr denkt, aber bei 2 wären sie immerhin schon ne halbe Milliarde DM wert. Weiß nicht...  

 

*tröst*
naja,wär auch n heisser zock gewesen;)
muss nach us-opening auch ersma n paar liter adrenalin abduschen*g*
mfg kram